Related Experiment Video
Updated: Oct 13, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
2.0K
Hydroxychloroquine in IgA nephropathy: a systematic review.
Gabriel Stefan1,2, Gabriel Mircescu1,2
1Department of Nephrology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Renal Failure
|November 15, 2021
Summary
Hydroxychloroquine (HCQ) may reduce proteinuria in IgA nephropathy (IgAN) patients when compared to supportive care. Further research is needed to confirm HCQ's efficacy against other treatments.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- IgA nephropathy (IgAN) is a kidney disease characterized by proteinuria.
- Hydroxychloroquine (HCQ) has emerged as a potential therapeutic agent for IgAN.
- Evidence regarding HCQ's efficacy and safety in IgAN requires systematic evaluation.
Purpose of the Study:
- To systematically review the benefits and risks of Hydroxychloroquine (HCQ) therapy in IgA nephropathy (IgAN) patients.
- To summarize existing evidence on HCQ's impact on proteinuria and renal function in IgAN.
- To assess HCQ as an anti-proteinuric agent in IgAN.
Main Methods:
- Systematic review of randomized, cohort, and case-control studies.
- Inclusion of biopsy-proven IgAN patients.
- Comparison of HCQ with ACE inhibitors/ARBs or immunosuppression for proteinuria reduction.
Main Results:
- Five studies (1 randomized, 3 observational) with 504 patients were included.
- HCQ showed a tendency to reduce proteinuria, significantly when compared to supportive therapy at 6 months.
- No significant difference in proteinuria reduction was observed when HCQ was compared to immunosuppressive therapy; HCQ did not impact eGFR.
Conclusions:
- HCQ may be an effective alternative for IgAN patients unresponsive to conventional therapies.
- Further ethnically diverse, randomized controlled trials with long-term follow-up are necessary.
- HCQ demonstrates potential as an anti-proteinuric agent in IgAN management.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
748
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
748
01:28Chronic Kidney Disease III: Interprofessional Care
107
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
107
01:25Antihypertensive Drugs: Direct Renin Inhibitors
896
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
896
01:26Nephrotic Syndrome II : Assessment and Medical Management
35
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
35
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
01:24Chronic Kidney Disease II: Clinical Manifestations
149
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
149